MeiraGTx Holdings (MGTX) Stock Overview
A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MGTX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MeiraGTx Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.80 |
| 52 Week High | US$13.63 |
| 52 Week Low | US$6.45 |
| Beta | 1.26 |
| 1 Month Change | 30.61% |
| 3 Month Change | 39.43% |
| 1 Year Change | 84.97% |
| 3 Year Change | 84.17% |
| 5 Year Change | -16.12% |
| Change since IPO | -14.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| MGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.3% | 5.1% | 1.9% |
| 1Y | 85.0% | 40.0% | 20.3% |
Return vs Industry: MGTX exceeded the US Biotechs industry which returned 40% over the past year.
Return vs Market: MGTX exceeded the US Market which returned 20.3% over the past year.
Price Volatility
| MGTX volatility | |
|---|---|
| MGTX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MGTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MGTX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 409 | Alexandria Forbes | www.meiragtx.com |
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
MeiraGTx Holdings plc Fundamentals Summary
| MGTX fundamental statistics | |
|---|---|
| Market cap | US$1.25b |
| Earnings (TTM) | -US$120.53m |
| Revenue (TTM) | US$79.76m |
Is MGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGTX income statement (TTM) | |
|---|---|
| Revenue | US$79.76m |
| Cost of Revenue | US$3.66m |
| Gross Profit | US$76.10m |
| Other Expenses | US$196.63m |
| Earnings | -US$120.53m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 95.41% |
| Net Profit Margin | -151.12% |
| Debt/Equity Ratio | -128.3% |
How did MGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/01 21:55 |
| End of Day Share Price | 2026/07/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MeiraGTx Holdings plc is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |